Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iptacopan - CFB inhibitor Study Indication Phase NCT03832114 (CLNP023X2202) C3 glomerulopathy (C3G) Phase 2 Patients 27 NCT03955445 (CLNP023B12001B) C3 glomerulopathy (C3G) Phase 2 27 Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication Cohort A: Ratio to Baseline of UPCR to Week 12 derived from 24hr urine collection Cohort B: Change from Baseline in C3 Deposit Score (based on immunofluorescence microscopy) at Week 12 Increasing doses of LNP023 up to 200mg bid: Cohort A: Native kidney patients Cohort B: Kidney transplanted patients Patients with C3 glomerulopathy H1-2021 (actual) Actual: Interim analysis data from Cohort-A presented at American Society of Nephrology (ASN 2020). Planned: Note not to be communicated externally until accepted. 1) Planned abstract at ERA-EDTA, Q3 2021 2) Planned abstract at ASN, Q4 2021 Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy 2025 Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 67 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation